You are here

Article Text

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Abstracts accepted for publication. Rheumatoid arthritis - other biologic treatment
AB0443 Influence of the Reason for Discontinuation of Previous TNF Antagonists on the Retention of Tocilizumab
  1. N. Asai1,
  2. T. Kojima1,
  3. A. Kaneko2,
  4. Y. Yabe3,
  5. T. Shioura4,
  6. K. Saito5,
  7. T. Kobayakawa6,
  8. N. Ishiguro1
  1. 1Department of Orthopedic Surgery, Nagoya University School Of Medicine
  2. 2Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya
  3. 3Department of Rheumatology, Tokyo KouseiNenkin Hospital, Tokyo
  4. 4Department of Orthopedic Surgery, Shizuoka Kousei Hospital, Shizuoka
  5. 5Saito Clinic, Nagoya
  6. 6Department of Orthopedic Surgery, Gifu Social Insurance Hospital, Kani, Japan

Abstract

Background Tocilizumab (TCZ) is effective for rheumatoid arthritis (RA) patients with inadequate responses to tumor necrosis factor (TNF) antagonists. However, it has not yet been established whether the type of failure that motivated the switch from TNF antagonists influences the retention of TCZ.

Objectives The present study was undertaken to investigate the relationship between the retention of TCZ and the reason for discontinuation of previous TNF antagonists in RA patients.

Methods This study included 181 RA patients who switched from TNF antagonists to TCZ therapy in Tsurumai Biologics Communication Registry (TBCR). The continuation rates and causes of discontinuation of TCZ were compared between two groups divided by the reasons for discontinuation of previous TNF antagonists (142 patients with inefficacy and 25 patients with adverse events).

Results The continuation rate of TCZ after 2 years in patients with inefficacy (76.8%) was significantly higher compared with patients with adverse events (56.0%). At the rate of discontinuation of TCZ due to inefficacy, no significance was shown between the two groups (9.2% vs 4.0%). On the other hand, the rate of discontinuation of TCZ due to adverse events in patients with inefficacy was significantly lower than patients with adverse events (6.3% vs 36.0%).

Conclusions RA patients who switched from TNF antagonists due to inefficacy to TCZ have high rates of continuation.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.2299

https://doi.org/10.1136/annrheumdis-2014-eular.2299

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.